Med Sci Monit:羟考酮预处理能同时减少快速顺序麻醉诱导中依托咪酯诱发的肌阵挛和罗库溴铵诱发的回避反应

2017-12-07 余晓旭 “罂粟花”微信号

依托咪酯和罗库溴铵通常被同时用于快速顺序诱导麻醉。然而,羟考酮预处理对肌阵挛和回避反应的影响并没有文献报道。本研究的目的是评估羟考酮预处理对快速顺序诱导麻醉中依托咪酯诱发的肌阵挛和罗库溴铵诱发的回避反应的发生率和严重程度的影响。

背景与目的:依托咪酯和罗库溴铵通常被同时用于快速顺序诱导麻醉。然而,羟考酮预处理对肌阵挛和回避反应的影响并没有文献报道。本研究的目的是评估羟考酮预处理对快速顺序诱导麻醉中依托咪酯诱发的肌阵挛和罗库溴铵诱发的回避反应的发生率和严重程度的影响。

方法:将120例患者随机分为盐水组(S组)和羟考酮组(O组)(每组60例)。 患者在给予0.3mg / kg依托咪酯前2分钟静脉给予0.05mg / kg羟考酮或生理盐水。 在依托咪酯给药后评价肌阵挛的发生率和严重程度,然后注射罗库溴铵,然后评价回避反应。

结果:依托咪酯和罗库溴铵连续给药后不随意运动发生的总频率O组明显低于S组(28.3% vs 90%,p <0.001)。依托咪酯注射后肌阵挛发生的总频率和3级严重程度发生的总例数O组明显低于S组(总频率:25.0% vs 63.3%; 3级严重程度的例数:0 vs 10,P <0.001)。罗库溴铵注射后回避反应发生的总频率和3级强度发生的总例数O组显着少于S组(总频率: 6.7% vs 73.3%;3级强度的例数: 0 vs 11,P <0.001)。

结论:羟考酮预处理能同时有效预防全身麻醉诱导期间依托咪酯诱发的肌阵挛和罗库溴铵诱发的回避反应。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984225, encodeId=ce10198422534, content=<a href='/topic/show?id=420681092f7' target=_blank style='color:#2F92EE;'>#肌阵挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81092, encryptionId=420681092f7, topicName=肌阵挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Apr 03 14:09:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948437, encodeId=d37f194843e4a, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Mar 04 06:09:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608331, encodeId=8cf9160833106, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 09 05:09:00 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
    2018-04-03 zxl729
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984225, encodeId=ce10198422534, content=<a href='/topic/show?id=420681092f7' target=_blank style='color:#2F92EE;'>#肌阵挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81092, encryptionId=420681092f7, topicName=肌阵挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Apr 03 14:09:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948437, encodeId=d37f194843e4a, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Mar 04 06:09:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608331, encodeId=8cf9160833106, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 09 05:09:00 CST 2017, time=2017-12-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984225, encodeId=ce10198422534, content=<a href='/topic/show?id=420681092f7' target=_blank style='color:#2F92EE;'>#肌阵挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81092, encryptionId=420681092f7, topicName=肌阵挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Tue Apr 03 14:09:00 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948437, encodeId=d37f194843e4a, content=<a href='/topic/show?id=44a48001672' target=_blank style='color:#2F92EE;'>#羟考酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80016, encryptionId=44a48001672, topicName=羟考酮)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/D2FD7704B41C9E22364B1E54ABB223BB/100, createdBy=1df22500220, createdName=ms1260584454294838, createdTime=Sun Mar 04 06:09:00 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608331, encodeId=8cf9160833106, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Dec 09 05:09:00 CST 2017, time=2017-12-09, status=1, ipAttribution=)]

相关资讯

FDA更新羟考酮新剂型的说明书

    2013年4月16日,美国食品与药物管理局(FDA)批准了奥施康定(通用名:盐酸羟考酮控释片)新剂型说明书的更新。更改后的说明书显示,因该药可能会导致滥用,为减少滥用可通过嗅吸法途径给药。   另外,与奥施康定的新剂型相比,原来的盐酸羟考酮控释片有同样的治疗获益,但其获益未超出药物滥用风险,因此FDA决定撤出其销售权,同时FDA将不接受或批准任何原来的盐酸羟考酮控释片的非专利